Navigation Links
Genzyme Announces Presentation of New Positive Data on Carticel(R)
Date:3/10/2008

st cell therapy to be approved by the FDA. First introduced in March of 1995, Carticel received accelerated approval from the FDA in August of 1997 after the FDA instituted specific cell therapy guidelines. Under accelerated approval, the FDA required Genzyme to conduct confirmatory post-marketing clinical studies. Genzyme successfully completed the confirmatory studies and, in June of 2007, the FDA deemed the commitment satisfied.

To learn more about Carticel please visit http://www.carticel.com.

Cell Therapy Expertise at Genzyme

Genzyme has more than a decade of experience in developing and manufacturing autologous cell therapy products that have been used to treat thousands of patients. Epicel(R) (cultured epidermal autografts), a cell therapy for treating patients with severe burns, is also manufactured by Genzyme. Together, Carticel and Epicel represent the first such products ever brought to market in the United States, providing Genzyme with superior scientific and commercial expertise in this field.

About Carticel

CARTICEL is for autologous use and is indicated for the repair of symptomatic cartilage defects of the femoral condyle (medial, lateral or trochlea), caused by acute or repetitive trauma, in patients who have had an inadequate response to a prior arthroscopic or other surgical repair procedure (e.g., debridement, microfracture, drilling/abrasion arthroplasty, or osteochondral allograft/autograft). CARTICEL should only be used in conjunction with debridement, placement of a periosteal flap and rehabilitation. The independent contributions of the autologous cultured chondrocytes and other components of the therapy to outcome are unknown. It is not indicated for the treatment of cartilage damage associated with generalized osteoarthritis. It is not recommended for patients whose knee meniscus has been surgically removed unless the patient has undergone surgical reco
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
2. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
3. Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML
4. Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Sono-Tek Corporation (OTC BB: SOTK) today ... 30, 2013, compared to sales of $2,202,000 for the prior ... this quarter has also shown growth over the preceding quarter,s ... of this fiscal year. Markets that experienced sales increases over ...
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ... Consumables Market - Global Industry Analysis, Size, Share, Growth, ... their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... are used on patients in order to treat dental ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Novation, the leading ... awarded several new IT value-added reseller (VAR) national contracts ... IT goods and services at lower costs. These include ... services such as initiative assistance and ongoing IT consulting ...
Breaking Medicine Technology:Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2
... Niiki Pharma Inc. announced today that it has ... clinical trial of its lead product, NKP-1339. NKP-1339 is ... tumor survival and anti-apoptosis factor. The NKP-1339 ... in patients with advanced solid tumors resistant to multiple, ...
... 2012 ULURU Inc. (NYSE AMEX: ULU ... European license for Altrazeal® to include the Middle East and ... the territory, Helmut Kerschbaumer Chairman of Melmed Holdings AG, stated, ... marketing to the various sectors in these markets. We have ...
Cached Medicine Technology:Niiki Pharma Announces the Completion of Phase I Dose Escalation for First-in-Man Anti-Cancer Agent NKP-1339 2ULURU Inc. Extends the European Altrazeal® License to Include the Middle East and Africa 2
(Date:7/11/2014)... The Corn Farming industry experienced ... the heels of fresh biofuel demand. The Federal Renewable ... larger share of their farmland to cultivating high-value corn ... the mixing of 5.0% renewable content in gasoline across ... States created a key export market for Canadian corn, ...
(Date:7/11/2014)... CA (PRWEB) July 11, 2014 Ticket ... Bryan Tickets at the Sleep Train Amphitheatre in Wheatland, ... venues that can compare to what the Sleep Train Amphitheatre ... musical events and special attractions over the course of its ... 16th, the Sleep Train Amphitheatre in Wheatland (Sacramento metro area) ...
(Date:7/11/2014)... are insoluble colorants, which usually consist of inorganic compounds. ... and coloring. These are water and oil insoluble natural ... as paper, paints, plastics, and concrete. Binders are used ... to the substance. Some examples of pigments are titanium ... coloring action of pigments is due to the scattering ...
(Date:7/11/2014)... York, NY (PRWEB) July 11, 2014 ... dramatic increase in men seeking cosmetic surgery and hair ... year. With such an expansive range of medical tourism ... exceptional plastic surgery costs and achieve the ... to be renowned as the top name in the ...
(Date:7/11/2014)... prescribed exercise as medicine, according to a QUT ... is essential to reducing the risk of death ... QUT,s Institute of Health and Biomedical Innovation, said ... and mental health, health professionals should be prescribing ... Anderson and QUT,s Dr Charlotte Seib co-authored a ...
Breaking Medicine News(10 mins):Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 2Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 3Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 2Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 3Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 2Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 3Health News:VisitandCare.com Reports Increase in Cosmetic and Hair Transplant Procedures for Men 2Health News:VisitandCare.com Reports Increase in Cosmetic and Hair Transplant Procedures for Men 3Health News:Exercise is the best medicine: QUT study 2
... , CHARLOTTE, N.C., July 17 ... an affiliate of US HIFU -- a worldwide leader in ... focused ultrasound (HIFU) technologies -- officially launches Sonablate((R)) HIFU services ... Gandhi Cancer Institute & Research Centre (RGCI & RC) on ...
... Gene, brain activity may determine child,s temperament, study finds , ... easy baby or a fussy one may have nothing to ... certain gene and a particular pattern of brain activity may ... Canadian researchers examined the interaction between the DRD4 gene and ...
... remain volatile issues in the drive for bipartisan support , ... to overhaul the nation,s health-care system started to emerge from ... that this may, at long last, be the year that ... health care more affordable. , "I think we,re in a ...
... , DOYLESTOWN, Pa., July 17 The ... www.quigleyco.com , today announced that Ted Karkus, ... Executive Officer by the Board of Directors of the Company. The ... Chief Operating Officer. , , ...
... July 17 Masimo Corporation (Nasdaq: MASI ), ... pending litigation under which Masimo and Respironics will dismiss all claims and ... As part of the settlement, Respironics and Masimo have agreed upon ... , About Masimo , ...
... TSX: BMR , , TORONTO, July 17 /PRNewswire-FirstCall/ ... "Corporation") announced today that its Board of Directors has ... bid (the "Offer"), pursuant to which the Corporation will ... of its outstanding common shares ("Shares") at a price ...
Cached Medicine News:Health News:Innovative Prostate Cancer Treatment Known as Sonablate(R) HIFU Now Available at Third Site in India 2Health News:Easy Baby or Fussy -- It May Be Out of Mom's Control 2Health News:Congress Braces for Showdown Over Health-Care Reform 2Health News:Congress Braces for Showdown Over Health-Care Reform 3Health News:Ted Karkus Named CEO of The Quigley Corporation; Robert V. Cuddihy, Jr. Named Chief Operating Officer 2Health News:Ted Karkus Named CEO of The Quigley Corporation; Robert V. Cuddihy, Jr. Named Chief Operating Officer 3Health News:Ted Karkus Named CEO of The Quigley Corporation; Robert V. Cuddihy, Jr. Named Chief Operating Officer 4Health News:Masimo Announces Settlement of Lawsuit 2Health News:Masimo Announces Settlement of Lawsuit 3Health News:Bradmer to repurchase up to 8.3 million of its common shares pursuant to a substantial issuer bid 2Health News:Bradmer to repurchase up to 8.3 million of its common shares pursuant to a substantial issuer bid 3Health News:Bradmer to repurchase up to 8.3 million of its common shares pursuant to a substantial issuer bid 4
... is an effective angina relief ... poor targets. Because it is ... the CO2 Heart Laser 2 ... timely operative decisions to revascularize ...
Ultrasensitive TSH EIA Thyroid Function 025-BC-1003...
TG (Ab) RIA Thyroid Function 014-HD 27.1 Thyroglobulin...
... The anti-TG test kit is a solid ... format. It is designed for the quantitative ... (TG) in serum or plasma. The microplate ... Calibrators, controls and patient samples are pipetted ...
Medicine Products: